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Lymphangioleiomyomatosis  is  a  multisystem  disease
ffecting  women,  which  is  characterized  by  cystic  lung
estruction,  lymphatic  abnormalities  (e.g.,  lymphangi-
leiomyomas),  and  abdominal  tumors  which  are  found
rimarily  in  the  kidneys,  and  consist  of  smooth  mus-
le  cells,  vascular  structures  and  adipocytes,  termed
ngiomyolipomas.1,2 Lymphangioleiomyomatosis  occurs  spo-
adically  and  in  about  one-third  of  women  with  tuberous
clerosis  complex  (TSC),  an  autosomal  dominant  disorder
ith  variable  penetrance.1,2 In  either  case,  LAM  is  caused
y  mutations  of  TSC1  or  TSC2, two  genes  that  encode,
espectively,  hamartin  and  tuberin,  two  proteins  that  reg-
late  cell  growth.3,4 Deﬁciency  of  these  proteins  causes
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oi:10.1016/j.rppneu.2012.02.005ctivation  of  mammalian  target  of  rapamycin  (mTOR)  down-
tream  elements,  leading  to  increased  cell  proliferation  and
ize  (Fig.  1).
Sporadic  lymphangioleiomyomatosis  is  a  rare  disease
ccurring  in  circa  2--5/1,000,000  persons.1,2 Yet,  for  those
fﬂicted,  LAM  is  devastating.  Progressive  lung  destruction
eads  to  respiratory  failure,  lung  transplantation  or  death.1,2
ymphatic  involvement  may  cause  chylous  pleural  effusions,
scites  and  lymphangioleiomyomas,  abdominal  tumors  that
ay  mimic  lymphomas  and  sarcomas.5 Renal  angiomy-
lipomas  may  be  associated  with  abdominal  hemorrhage,
equiring  partial  or  total  nephrectomy  or  embolization  of
rterial  feeding  vessels.6
In  the  past,  patients  with  LAM  were  advised  to
ndergo  bilateral  oophorectomy  and  hysterectomy  and/or
e  treated  with  anti-estrogen  agents  such  as  progesterone  or
onadotropin-releasing  hormone  analogues.  No  controlled
tudies  showing  that  these  therapies  are  beneﬁcial  to  the
atients  have  ever  been  carried  out.7,8
Several  studies  have  demonstrated  the  important  role  of
he  TSC1/TSC2  complex  in  cell  cycle  progression  and  in  cell
ize  and  proliferation.9,10 Tuberin  binds  a  cyclin-dependent
inase  inhibitor,  thus  stabilizing  it,  resulting  in  inhibition  of
ell  cycle  progression.  Tuberin  also  has  a  GTPase  activat-
ng  protein  activity,  which  converts  Ras  homolog  enriched  in
rain  (Rheb)-GTP  to  Rheb-GDP,  resulting  in  inactivation  of
heb  (Fig.  1)  and  reduction  in  activity  of  mTOR,  a  kinase  that
ontrols  translation  through  the  phosphorylation  of  4E-BP1
nd  S6K1  (Fig.  1).  Protein  kinase  B  (Akt),  when  activated  by
rowth  factors,  phosphorylates  and  inhibits  tuberin,  result-
ng  in  increased  cell  size  and  proliferation.9,10
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Figure  1  Simpliﬁed  schematic  model  of  TSC1  and  TSC2  path-
ways. The  TSC1/TSC2  complex  has  roles  in  cell  cycle  progression
and in  cell  size  and  proliferation.  This  complex  stimulates  the
conversion  of  active  Rheb-GTP  to  inactive  Rheb-GDP,  resulting
in inactive  Rheb.  Rheb  controls  mTOR,  a  kinase  that  controls
translation  through  phosphorylation  of  S6K1.  Sirolimus  inhibits
mTOR.  Abbreviations:  PI3K:  phosphoinositide  3-kinase;  Akt:
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protein  kinase  B;  mTOR:  mammalian  target  of  rapamycin;  Rheb
GAP: GTPase-activating  protein  for  Ras  homolog  enriched  in
brain; S6K1:  S6  kinase  1  (modiﬁed  from  Ref.  10).
Sirolimus  (Rapamycin),  in  the  presence  of  FKBP12  (FK506-
binding  protein),  inhibits  mTOR.  Animal  models  with  a
functionally  null  germline  mutation  of  Tsc2  spontaneously
develop  renal  cell  carcinomas  which  decrease  in  size  fol-
lowing  administration  of  sirolimus.11,12 In  patients  with
angiomyolipomas,  tumor  size  decreased  by  half  after
1  year  of  sirolimus  therapy,  while  lung  function  improved
in  some  patients  but  not  in  others.13 Other  studies  have
shown  that  sirolimus  therapy  leads  to  resolution  of  chy-
lous  effusions  in  post-transplant  LAM  patients,14 decreased
the  size  of  giant  cell  astrocytomas  and  reduced  the  fre-
quency  of  seizures  in  TSC  patients.15 Results  of  a  multicenter
placebo-controlled  randomized  trial  just  completed  (MILES
trial),  showed  that  sirolimus  stabilized  lung  function,  and
improved  symptoms  and  quality  of  life  in  patients  with
LAM.16 There  was  a  highly  signiﬁcant  difference  in  the
change  in  lung  function  over  1  year  of  therapy  betweenench  to  bedside  143
irolimus-treated  and  placebo-treated  patients.16 In  another
tudy,  sirolimus  therapy  improved  chylous  effusions  and/or
ymphangioleiomyomas.17 By  3--6  months  of  therapy,  effu-
ions  start  to  resolve  and  complete  resolution  may  be
bserved,  pre-empting  the  need  for  repeated  thoracentesis,
hest  tube  drainage  or  pleurodesis.17
These  observations  provide  the  rationale  for  the  use
f  sirolimus  in  the  treatment  of  selected  LAM  patients.
irolimus  therapy  may  be  considered  for  patients  that
ulﬁll  the  inclusion/exclusion  criteria  for  MILES,  those
ith  rapidly  progressing  lung  disease,  those  with  chy-
ous  effusions  that  compromise  the  lung  function  and
equire  frequent  drainage  or  pleurodesis,  and  patients  with
arge  symptomatic  thoraco-abdominal  lymphangioleiomy-
mas.  The  starting  dose  of  sirolimus  is  2  mg/day.  Sirolimus
evels  must  be  monitored  and  dosage  adjusted  to  attain
erum  trough  levels  between  5  and  15  ng/ml,  a  range
hought  to  be  therapeutic  for  patients  with  renal  trans-
lants.  The  occurrence  of  adverse  events  associated  with
irolimus  therapy,  such  as,  oral  mucosa  ulcers,  hypertension,
yperlipidemia,  proteinuria,  increased  serum  creatinine,
nfections,  and  sirolimus-related  interstitial  pneumonitis,
andate  close  patient  monitoring,  and  may  require  with-
olding  of  the  drug  or  reduction  in  dose.  In  addition,  given
he  limited  experience  with  sirolimus  in  the  treatment  of
AM,  it  is  not  known  whether  treatment  may  have  to  be  con-
inued  for  life,  when  it  should  be  started,  the  optimal  drug
evels,  or  if  sirolimus  resistance  will  eventually  develop.
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